Genta Incorporated (OTCBB: GNTA.OB) announced today that the Company
will release its financial results for the third quarter 2008 on
Thursday, November 6, 2008. Genta management will host a conference call
and live audio webcast to discuss financial results and corporate
activities on that date at 8:00 am ET.
Participants can access the live call by dialing (877) 634-8606 (U.S.
and Canada) or (973) 200-3973 (International). The access code for the
live call is Genta Incorporated. The call will also be webcast live at http://www.genta.com/investorrelation/events.html.
For investors unable to participate in the live call, a replay will be
available approximately two hours after the completion of the call, and
will be archived for 30 days. Access numbers for this replay are: (800)
642-1687 (U.S. and Canada) and (706) 645-9291 (International);
conference ID number is 70101499.
About Genta
Genta Incorporated is a biopharmaceutical company with a diversified
product portfolio that is focused on delivering innovative products for
the treatment of patients with cancer. Two major programs anchor the
Company’s research platform: DNA/RNA-based
Medicines and Small Molecules. Genasense®
(oblimersen sodium) Injection is the Company's lead compound from its
DNA/RNA Medicines program. Genta is currently recruiting patients to the
AGENDA Trial, a global Phase 3 trial of Genasense in patients with
advanced melanoma. The leading drug in Genta’s
Small Molecule program is Ganite® (gallium
nitrate injection), which the Company is exclusively marketing in the
U.S. for treatment of symptomatic patients with cancer-related
hypercalcemia that is resistant to hydration. The Company has developed
G4544, an oral formulation of the active ingredient in Ganite, that has
recently entered clinical trials as a potential treatment for diseases
associated with accelerated bone loss. The Company is also developing
tesetaxel, a novel, orally absorbed, semi-synthetic taxane that is in
the same drug class as paclitaxel and docetaxel. Ganite and Genasense
are available on a "named-patient”
basis in countries outside the United States. For more information about
Genta, please visit our website at: www.genta.com.
Safe Harbor
This press release may contain forward-looking statements with
respect to business conducted by Genta Incorporated. By their nature,
forward-looking statements and forecasts involve risks and uncertainties
because they relate to events and depend on circumstances that will
occur in the future.
Forward-looking statements include, without
limitation, statements about:
-
the Company’s ability to obtain
necessary regulatory approval for Genasense®
from the U.S. Food and Drug Administration ("FDA”)
or European Medicines Agency ("EMEA”);
-
the safety and efficacy of the Company’s
products or product candidates;
-
the Company’s assessment of its clinical
trials;
-
the commencement and completion of clinical trials;
-
the Company’s ability to develop,
manufacture, license and sell its products or product candidates;
-
the Company’s ability to enter into and
successfully execute license and collaborative agreements, if any;
-
the adequacy of the Company’s capital
resources and cash flow projections, the Company’s
ability to obtain sufficient financing to maintain the Company’s
planned operations, or the Company’s risk
of bankruptcy;
-
the adequacy of the Company’s patents
and proprietary rights;
-
the impact of litigation that has been brought against the Company;
and
-
the other risks described under Certain Risks and Uncertainties
Related to the Company’s Business, as
contained in the Company’s Annual Report on
Form 10-K and Quarterly Report on Form 10-Q.
The Company does not undertake to update any forward-looking
statements.
There are a number of factors that could cause actual
results and developments to differ materially.
For a discussion
of those risks and uncertainties, please see the Company's Annual Report
on Form 10-K for 2007 and its most recent quarterly report on Form 10-Q.
